| 章敏巧.非布司他治疗慢性肾脏病3-5 期合并高尿酸血症的有效性和安全性观察[J].浙江中西医结合杂志,2017,27(5): |
| 非布司他治疗慢性肾脏病3-5 期合并高尿酸血症的有效性和安全性观察 |
| Research on the efficacy and safety of febuxostat in chronic kidney disease of stage 3～5 patients with hyperuricemia |
| 投稿时间：2016-11-05 修订日期：2016-12-28 |
| DOI： |
| 中文关键词: 非布司他片 碳酸氢钠片 慢性肾脏病(CKD) 高尿酸血症 |
| 英文关键词:febuxostat sodium hydrogen carbonate chronic kidney disease (CKD) hyperuricemia |
| 基金项目: |
|
| 摘要点击次数: 840 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的S观察非布司他治疗慢性肾脏病3-5期合并高尿酸血症的有效性和安全性。方法S选取2016年1月~6月在我院肾内科就诊和治疗的70S例慢性肾脏病3-5期合并高尿酸血症患者,随机分成对照组和治疗组,每组各35S例。所有患者均给予低盐低嘌呤优质低蛋白饮食,并给予慢性肾功能不全的常规治疗。治疗组非布司他片40 mg,口服,1S次/日; 对照组碳酸氢钠片1.0g,口服,3S次/日。两组均连续治疗16S周。观察两组的临床疗效和安全性,在治疗前及治疗后第1、2、4、8、12、16S周检查生化指标血尿酸(SUA)、血肌酐(Scr)、血尿素氮(BUN)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、血浆白蛋白(ALB)及血常规相关指标白细胞(WBC)计数、血红蛋白(HB)。结果S治疗组患者治疗前后SUA、Scr、BUN差异有统计学意义(P＜0.001),对照组患者治疗前后SUA、Scr、BUN差异有统计学意义(P＜0.05),治疗16周后治疗组血尿酸水平下降较对照组明显,具有统计学差异(P＜0.001)。两组患者治疗前后ALT、AST、ALB、WBC、HB均无明显改变,差异无统计学意义。且所有患者未出现胃肠道等不良反应。结论S对于慢性肾脏病3-5期合并高尿酸血症患者,接受非布司他治疗可获得良好的降血尿酸效果,同时安全性好,无明显不良反应。 |
| 英文摘要: |
| Objective: To observe the efficacy and safety of febuxostat in chronic kidney disease of stage 3～5 patients with hyperuricemia.Methods: 70 patients with chronic kidney disease of stage 3～5 with hyperuricemia in our hospital from January to June of 2016 were included. They were randomly divided into two groups: treatment group (n=35) and control group (n=35). Except the treatment of chronic kidney disease, all the patients were given low-salt, low-purine and low-protein diet. The treatment group were treated with febuxostat(40mg qd) for 16 weeks, while the control group were treated with sodium hydrogen carbonate (1.0g tid) for the same time. The serum uric acid(SUA), serum creatinine(Scr), blood urea nitrogen(BUN), ALT, AST, plasma albumin(ALB), white blood cell(WBC) and hemoglobin(Hb) were detected at before treatment and 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16weeks after treatment. Results: There was a remarkable difference in the levels of SUA, Scr and BUN before and after treatment in treatment group (p<0.001), there was also a difference between before and after treatment in control group (p<0.05). The changes of the levels of SUA, Scr and BUN were significiant differences in the treatment group comparing with the control group (P < 0.001). The levels of ALT, AST, ALB, WBC and Hb had no significant change before and after treatment in two groups. No adverse reaction was founded in two groups.Conclusion: Patients with hyperuricemia in chronic kidney disease of stage 3～5 treated with febuxostat is effective and safe. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
